An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact for patients with primary hyperoxaluria who completed study OC5-DB-02
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- Acronyms ePHex OLE
- Sponsors OxThera
Most Recent Events
- 03 Sep 2021 Status changed from active, no longer recruiting to discontinued.
- 13 Aug 2021 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 29 Jul 2021 This trial has been discontinued in Belgium, according to European Clinical Trials Database record.